Form 4: Roivant Sciences Executive Settles Capped Value Appreciation Rights for Common Shares

Mayukh Sukhatme, President and Chief Investment Officer of Roivant Sciences, settled capped value appreciation rights (CVARs) for common shares and reported tax withholding transactions.

Summary

• Mayukh Sukhatme, President and Chief Investment Officer of Roivant Sciences Ltd., reported changes in beneficial ownership to the SEC on April 2, 2024.
• The report details the settlement of 1,856,163 capped value appreciation rights (CVARs) into 729,081 common shares on March 30, 2024.
• The 'knock-in' condition and hurdle price for the CVARs were satisfied, leading to the settlement.
• The settlement was calculated based on the CVAR Amount divided by the closing price of a Common Share on March 28, 2024.
• The report also reflects a 'net settlement' by Roivant Sciences of CVARs to cover tax withholding obligations, resulting in the disposition of 366,211 common shares at a price of $10.54.
• Sukhatme directly owns 3,651,985 common shares and indirectly owns 1,657,698 common shares through a limited liability company (LLC).
• The LLC holds restricted stock awards (RSAs) that are fully vested, and Sukhatme has investment control over the LLC and its parent family trust.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing the settlement of previously awarded compensation. It doesn't contain any particularly positive or negative news, but reflects the ongoing operation of the company's compensation plans.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders and their holdings in the company's securities. This filing indicates the vesting and settlement of previously awarded compensation in the form of CVARs.

Comparison to Industry Standards

• Comparing Roivant Sciences' executive compensation structure with similar biotech companies reveals a common use of equity-based incentives like stock options, restricted stock units (RSUs), and performance-based awards.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar instruments to align executive interests with shareholder value.
• The specific terms of Roivant's CVARs, such as the hurdle price and cap, would need to be benchmarked against industry peers to assess their relative attractiveness and potential impact on executive compensation.

Stakeholder Impact

• The settlement of CVARs into common shares may have a minor dilutive effect on existing shareholders.
• The tax withholding transactions could slightly impact the company's cash position.

Key Dates